Citi sees Gilead clinical holds as only ‘minor setback’

finance.yahoo.com/news/citi-sees-gilead-clinical-holds-142019013.html

In This Article:
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated…

This story appeared on finance.yahoo.com, 2025-06-11 14:20:19.
The Entire Business World on a Single Page. Free to Use →